Discontinued — last reported Q4 '25
Business Segments · Goodwill
Pharmaceuticalsegment — Goodwill
Merck & Co. Pharmaceuticalsegment — Goodwill increased by 0.0% to $17.91B in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 0.0%, from $17.90B to $17.91B.
Analysis
StatementSegment
CategoryCapital Allocation
SignalContext dependent
VolatilityStable
First reportedQ4 2013
Last reportedQ4 2025
Rolls up toGoodwill
How to read this metric
An increase suggests recent acquisitions, while a decrease may indicate impairment charges due to declining business value.
Detailed definition
Represents the intangible asset value arising from the acquisition of pharmaceutical businesses where the purchase price...
Peer comparison
Common across large-cap pharma peers following M&A activity; high levels relative to equity may signal overpayment risk.
Metric ID:
mrk_segment_pharmaceutical_segment_goodwillHistorical Data
5 periods
| Q4 '21 | Q4 '22 | Q4 '23 | Q4 '24 | Q4 '25 | |
|---|---|---|---|---|---|
| Value | $18.00B | $17.94B | $17.92B | $17.90B | $17.91B |
| QoQ Change | — | -0.3% | -0.1% | -0.1% | +0.0% |
| YoY Change | — | -0.3% | -0.1% | -0.1% | +0.0% |
Range$17.90B – $18.00B
CAGR-0.5%
Avg YoY Growth-0.1%
Median YoY Growth-0.1%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Merck & Co.'s pharmaceuticalsegment — goodwill?
- Merck & Co. (MRK) reported pharmaceuticalsegment — goodwill of $17.91B in Q4 2025.
- How has Merck & Co.'s pharmaceuticalsegment — goodwill changed year-over-year?
- Merck & Co.'s pharmaceuticalsegment — goodwill increased by 0.0% year-over-year, from $17.90B to $17.91B.
- What does pharmaceuticalsegment — goodwill mean?
- The premium paid for acquiring pharmaceutical businesses above their net asset value.